Resource utilization for chimeric antigen receptor T cell therapy versus autologous hematopoietic cell transplantation in patients with B cell lymphoma

CD19-directed chimeric antigen receptor T cells (CAR-T) have emerged as a highly efficacious treatment for patients with relapsed/refractory (r/r) B cell lymphoma (BCL). The value of CAR-T for these patients is indisputable, but one-off production costs are high, and little is known about the ancill...

Descripción completa

Detalles Bibliográficos
Autores principales: Ring, Alexander, Grob, Björn, Aerts, Erik, Ritter, Katharina, Volbracht, Jörk, Schär, Bettina, Greiling, Michael, Müller, Antonia M. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279251/
https://www.ncbi.nlm.nih.gov/pubmed/35759026
http://dx.doi.org/10.1007/s00277-022-04881-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279251/
https://www.ncbi.nlm.nih.gov/pubmed/35759026
http://dx.doi.org/10.1007/s00277-022-04881-0

Ejemplares similares